Epic Sciences has announced it raised $30 million in financing.

Epic Sciences, headquartered in San Diego, Calif., is a biotech company developing diagnostic tests to molecularly characterize circulating tumor cells (CTC) in the blood.

The $30 million series C preferred stock financing included new investors RusnanoMedInvest  and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund and Pfizer Venture Investments, and undisclosed individual investors.

Epic indicated the proceeds of the financing would go toward commercializing its circulating rare cell analysis platform with special focus on developing products and services to detect CTC in cancer.